Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Clinical and Experimental Medicine (Testo stampato)

• Publication date

  2020-02-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10238-020-00612-9PMID 32026157
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Volume Computed Tomography Perfusion Imaging: Evaluation of the Significance in Oncologic Follow-up of Metastasizing Renal Cell Carcinoma in the Early Period of Targeted Therapy — Preliminary Results

  2019cited by this paper
• MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma

  2019cited by this paper
• The long-term rapid increase in incidence of adenocarcinoma of the kidney in the USA, especially among younger ages.

  2019cited by this paper
• Differential diagnosis of the small renal masses: role of the apparent diffusion coefficient of the diffusion-weighted MRI

  2018cited by this paper
• FDG PET/CT as a survival prognostic factor in patients with advanced renal cell carcinoma

  2018cited by this paper
• Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals

  2018cited by this paper
• Histogram analysis of apparent diffusion coefficient from whole-body diffusion-weighted MRI to predict early response to chemotherapy in patients with metastatic colorectal cancer: preliminary results.

  2018cited by this paper
• Systemic Therapy for Metastatic Renal-Cell Carcinoma.

  2017cited by this paper
• Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F–Fluorodeoxyglucose (18F–FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study

  2017cited by this paper
• Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma In Vivo with Susceptibility Contrast MRI.

  2017cited by this paper
• Marital status and survival of patients with kidney cancer

  2017cited by this paper
• Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.

  2017cited by this paper
• Renal cell carcinoma: applicability of the apparent coefficient of the diffusion-weighted estimated by MRI for improving their differential diagnosis, histologic subtyping, and differentiation grade

  2017cited by this paper
• Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma

  2017cited by this paper
• Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma

  2017cited by this paper
• Molecular Imaging to Predict Response to Targeted Therapies in Renal Cell Carcinoma

  2017cited by this paper
• Radiomics Analysis on FLT-PET/MRI for Characterization of Early Treatment Response in Renal Cell Carcinoma: A Proof-of-Concept Study

  2016cited by this paper
• VEGF mediated signaling in oral cancer.

  2016cited by this paper
• Use of DWI in the Differentiation of Renal Cortical Tumors.

  2016cited by this paper
• Platelet‐derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape

  2015cited by this paper
• Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.

  2015cited by this paper
• 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.

  2014cited by this paper
• Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance.

  2014cited by this paper
• Value of the Diffusion-Weighted MRI in the Differential Diagnostics of Malignant and Benign Kidney Neoplasms – Our Clinical Experience

  2014cited by this paper
• Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma

  2013cited by this paper
• External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.

  2013cited by this paper
• Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib

  2011cited by this paper
• CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies

  2010cited by this paper
• Use of modified RECIST criteria to improve response assessment in targeted therapies: Challenges and opportunities

  2010cited by this paper
• From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

  2009cited by this paper

• Differentiation of solid and cystic small renal masses: the role of multiphase CT markers in predicting malignant histology, subtype, and grade

  2025cites this paper
• Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring

  2023cites this paper
• The use of Doppler vascular resistance in the early diagnosis of chronic kidney disease progression in patients with renal cell carcinoma

  2022cites this paper
• Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma

  2022cites this paper
• Local recurrence of renal cell carcinoma after partial nephrectomy: applicability of the apparent diffusion coefficient of MRI as an imaging marker – a multicentre study

  2022cites this paper
• Pre-trial quality assurance of diffusion-weighted MRI for radiomic analysis and the role of harmonisation.

  2022cites this paper
• Application of different methods used to measure the apparent diffusion coefficient of renal cell carcinoma on the same lesion and its correlation with ISUP nuclear grading

  2022cites this paper
• Personalized management of prostate cancer: from molecular and imaging markers to radiogenomics

  2022cites this paper
• Cancer Detection and Quantification of Treatment Response Using Diffusion-Weighted MRI

  2021cites this paper
• THE ROLE OF THE APPARENT DIFFUSION COEFFICIENT OF THE BIPARAMETRIC MRI AS AN IMAGING MARKER OF PROSTATE CANCER.

  2021cites this paper